COMPANY NEWS
Essex Bio-Technology establishes strategic collaboration with Biosparc Signs MOU with SIPIPO and Biosparc on International Innovation Accelerator
2025.11.21
Download
Hong Kong, 21 November 2025
EssexBio Pte. Ltd. a subsidiary of Essex Bio-Technology Limited (“EssexBio”, Stock Code: 1061.HK) has signed a Memorandum of Understanding (“MOU”) for strategic collaboration with Biosparc and Suzhou Industrial Park Investment Promotion and Operation Co., Ltd (“SIPIPO”) to establish an International Innovation Accelerator. The MOU was signed at the Biosparc - the China-Singapore Life Sciences Park Phase I ceremony, attended by representatives from Biosparc, SIPIPO, Temasek, A*Star and industry partners.
EssexBio Pte. Ltd. a subsidiary of Essex Bio-Technology Limited (“EssexBio”, Stock Code: 1061.HK) has signed a Memorandum of Understanding (“MOU”) for strategic collaboration with Biosparc and Suzhou Industrial Park Investment Promotion and Operation Co., Ltd (“SIPIPO”) to establish an International Innovation Accelerator. The MOU was signed at the Biosparc - the China-Singapore Life Sciences Park Phase I ceremony, attended by representatives from Biosparc, SIPIPO, Temasek, A*Star and industry partners.
With Phase I now complete, Biosparc is poised to become a premier cross-border life sciences hub, driving global research, product development, clinical development, and translational innovation. EssexBio aims to bolster its global innovation strategy and through this partnership, connecting with international collaborators to accelerate research, clinical development and commercialisation efforts.
~ End ~
About SIP
Suzhou Industrial Park, a local government authority. Its designated signing party, Suzhou Industrial Park Investment Promotion and Operation Co., Ltd. (SIPIPO), is a wholly state-owned enterprise tasked with driving investment promotion and supporting park-level development on behalf of the government.
About Biosparc
A dedicated life sciences park developed and operated by China-Singapore (Suzhou) Life Science Industry Development Co., Ltd., whose shareholders are Temasek, Sungent (a wholly state-owned developer under SIP with extensive experience in industrial park operations), and NRL (a healthcare-focused multi-platform asset manager).
About Essexbio (1061.HK)
Essex is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun(適麗順®) (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology.
These products are marketed and sold through approximately 14,100 hospitals, supported by the Company’s 46 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, Essex maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications.
Suzhou Industrial Park, a local government authority. Its designated signing party, Suzhou Industrial Park Investment Promotion and Operation Co., Ltd. (SIPIPO), is a wholly state-owned enterprise tasked with driving investment promotion and supporting park-level development on behalf of the government.
About Biosparc
A dedicated life sciences park developed and operated by China-Singapore (Suzhou) Life Science Industry Development Co., Ltd., whose shareholders are Temasek, Sungent (a wholly state-owned developer under SIP with extensive experience in industrial park operations), and NRL (a healthcare-focused multi-platform asset manager).
About Essexbio (1061.HK)
Essex is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun(適麗順®) (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology.
These products are marketed and sold through approximately 14,100 hospitals, supported by the Company’s 46 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, Essex maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications.
Related news
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China
2025-07-24
Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%
2024-03-18
Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%
2023-08-16
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
2023-07-26
Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready
2023-03-08
Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)
2021-10-27
Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia
2021-04-20
Essex-Biotechnology Announces Bevacizumab for wAMD Has Received Clinical Trial Approval in Australia
2021-01-29
Essex Bio-Technology and Antikor Biopharma Forge Strategic Alliance in FDC for Cancer Treatment
2019-08-02
粤公网安备 44049102496184号